{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360302865543489280.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s12282-023-01537-3"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/content/pdf/10.1007/s12282-023-01537-3.pdf"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/article/10.1007/s12282-023-01537-3/fulltext.html"}},{"identifier":{"@type":"DOI","@value":"10.21203/rs.3.rs-3409142/v1"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2025124204"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy"}],"description":[{"notation":[{"@value":"<jats:title>Abstract</jats:title>         <jats:p>Background  Electronic patient-reported outcomes monitoring (ePROM) is a useful communication tool for patients and healthcare providers in cancer chemotherapy. In this study, we examined the feasibility of our newly developed ePROM system, which we refer to as “Hibilog”. Methods  An ePROM app was developed by extracting 18 items from the Patient-Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE). Symptom monitoring was conducted every two weeks for patients with metastatic breast cancer undergoing chemotherapy. The primary outcome was the response rate to the ePROM system. The secondary outcomes were response time, item missing rate, and distribution of responses for each symptom. Results  A total of 71 cases (mean age 52.6 years) were analyzed. Performance status was 0 in 76% of the cases and 1 or higher in 24%. First-line treatment was being administered in 30% of cases, second-line treatment in 17%, and third-line or higher treatment in 53%. The response rate to the ePROM system from registration to week 40 remained high at around 80%, indicating good compliance. The average response time was 5.5 min and the missing rate for each item was below 0.3%. Among 1,093 responses, the top 3 symptoms causing interference with daily life were Fatigue (63%), Numbness & tingling (48%), and General pain (46%). Conclusion   Our developed ePROM system was able to capture symptoms accurately in patients with metastatic breast cancer undergoing chemotherapy while maintaining a high response compliance.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380302865543489322","@type":"Researcher","foaf:name":[{"@value":"Naruto Taira"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489296","@type":"Researcher","foaf:name":[{"@value":"Yuichiro Kikawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489320","@type":"Researcher","foaf:name":[{"@value":"Takayuki Iwamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489315","@type":"Researcher","foaf:name":[{"@value":"Yuichiro Miyoshi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489290","@type":"Researcher","foaf:name":[{"@value":"Kyoko Hara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489321","@type":"Researcher","foaf:name":[{"@value":"Seiji Yoshitomi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489286","@type":"Researcher","foaf:name":[{"@value":"Hajime Hikino"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489323","@type":"Researcher","foaf:name":[{"@value":"Hirotoshi Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489292","@type":"Researcher","foaf:name":[{"@value":"Daisuke Takabatake"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489311","@type":"Researcher","foaf:name":[{"@value":"Shinichiro Kubo"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489298","@type":"Researcher","foaf:name":[{"@value":"Masahiko Ikeda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489152","@type":"Researcher","foaf:name":[{"@value":"Hiroyoshi Doihara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489304","@type":"Researcher","foaf:name":[{"@value":"Tadahiko Shien"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489285","@type":"Researcher","foaf:name":[{"@value":"Hiromi Okuyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489295","@type":"Researcher","foaf:name":[{"@value":"Yuko Tanabe"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489283","@type":"Researcher","foaf:name":[{"@value":"Fumikata Hara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489301","@type":"Researcher","foaf:name":[{"@value":"Kosho Yamanouchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489284","@type":"Researcher","foaf:name":[{"@value":"Yasuhiro Hagiwara"}]},{"@id":"https://cir.nii.ac.jp/crid/1380302865543489305","@type":"Researcher","foaf:name":[{"@value":"Masataka Sawaki"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13406868"},{"@type":"EISSN","@value":"18804233"}],"prism:publicationName":[{"@value":"Breast Cancer"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2024-01-04","prism:volume":"31","prism:number":"2","prism:startingPage":"283","prism:endingPage":"294"},"reviewed":"false","dc:rights":["https://www.springernature.com/gp/researchers/text-and-data-mining","https://www.springernature.com/gp/researchers/text-and-data-mining"],"url":[{"@id":"https://link.springer.com/content/pdf/10.1007/s12282-023-01537-3.pdf"},{"@id":"https://link.springer.com/article/10.1007/s12282-023-01537-3/fulltext.html"},{"@id":"https://search.jamas.or.jp/link/ui/2025124204"}],"createdAt":"2024-01-04","modifiedAt":"2024-02-28","project":[{"@id":"https://cir.nii.ac.jp/crid/1040569382227248128","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"21K07383"},{"@type":"JGN","@value":"JP21K07383"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K07383/"}],"notation":[{"@language":"ja","@value":"高齢がん患者における新規分子標的薬及び抗がん薬によるケモブレイン予測モデルの開発"},{"@language":"en","@value":"Development of a risk tool for predicting chemo brain due to cancer treatment with new molecularly targeted therapy and chemotherapy in older patients"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360001114183925888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143561597056","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Electronic patient‐reported outcome systems in oncology clinical practice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017285976356864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021393542593408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021395479333248","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Feasibility and Acceptability to Patients of a Longitudinal System for Evaluating Cancer-Related Symptoms and Quality of Life: Pilot Study of an e/Tablet Data-Collection System in Academic Oncology"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021395480163456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302871124445312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effectiveness of routine provision of feedback from patient‐reported outcome measurements for cancer care improvement: a systematic review and meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302871124449536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302871984220672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093836136576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096136278656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576120739885952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580236934061312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584343747091840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584343747284224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584344424605952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Computerized Symptom and Quality-of-Life Assessment for Patients With Cancer Part I: Development and Pilot Testing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857596170756992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044546316672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520472745216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943982709120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Olaparib for Metastatic Breast Cancer in Patients with a Germline\n                    <i>BRCA</i>\n                    Mutation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945181423744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418970795904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421408794240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893493167104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Missing Voice of Patients in Drug-Safety Reporting"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893693299968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369799834880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Health-Related Quality-of-Life Assessments and Patient-Physician Communication"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370173771520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The effectiveness of the use of patient‐based measures of health in routine practice in improving the process and outcomes of patient care: a literature review"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795200308736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled Trial"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12282-023-01537-3"},{"@type":"KAKEN","@value":"PRODUCT-25501263"},{"@type":"OPENAIRE","@value":"doi_dedup___::ce5f530568f801b96115be9724f4e6cc"}]}